<DOC>
	<DOCNO>NCT00586339</DOCNO>
	<brief_summary>Infection human papillomavirus ( HPV ) clearly establish central cause cervical cancer . The current study design evaluate safety immunogenicity GlaxoSmithKline Biologicals ' HPV vaccine 580299 HIV infect adult female live Republic South Africa . The study double blind , randomize HIV positive subject open HIV negative subject . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Safety Immunogenicity GlaxoSmithKline Biologicals ' HPV Vaccine 580299 ( Cervarix TM ) HIV Infected Females</brief_title>
	<detailed_description />
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol A female , include , 18 25 year age time first vaccination . Written , sign thumbprinted informed consent obtain subject prior enrolment . Subjects willing undergo HIV Voluntary Counseling Testing ( VCT ) willing inform HIV status . Subjects willing provide place residence visit home . HIV seropositive subject : 1 . Subjects must HIV seropositive accord WHO case definition 2 . Subjects WHO Clinical Stage 1 HIVassociated disease 3 . Subjects currently antiretroviral therapy ( ART ) must compliant ART undetectable viral load HIV seronegative subject : Subjects confirm HIV seronegative screen visit eligible participate HIV/HPV group study . Nonvirgin subject must normal colposcopy screen visit . Nonvirgin subject must normal cervical cytology ( Pap smear ) great atypical squamous cell undetermined significance ( ASCUS ) screen visit . All subject must negative urine pregnancy test screen visit visit 1 ( Day 0 ) . Subjects must nonchildbearing potential , childbearing potential , must abstinent use adequate contraceptive precaution 30 day prior vaccination , negative pregnancy test must agree continue precaution two month completion vaccination series . Subjects must 6 lifetime sexual partner prior enrolment . Subjects must one single intact cervix Active tuberculosis ( TB ) Current TB prophylaxis therapy . Anemia screen visit . increase creatinine screen visit . Increased hepatic enzym ( ALT ) screen visit Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine/control , plan use entire study period ( Month 12 ) . Chronic administration immunosuppressant immunemodifying drug within 6 month prior first vaccine dose . Administration vaccine foreseen study protocol within 30 day first dose study vaccine/control . Enrolment postpone subject outside specify window . Planned administration vaccine foreseen study protocol within 30 day 30 day ( i.e. , Days 029 ) dose study vaccine . Previous vaccination HPV , plan administration HPV vaccine foreseen study protocol study period ( Month 0 Month 12 ) . previous administration component investigational vaccine Cancer autoimmune disease treatment . Hypersensitivity latex . History allergic disease reaction likely exacerbate component vaccine/control . Acute disease time enrolment . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory test perform screen visit . History neurological disorder seizure . Pregnant breastfeed female . A subject planning become pregnant , likely become pregnant ( determined investigator ) planning discontinue contraceptive precaution study period , two month last vaccine dose . Concurrently participate another clinical study , time study period ( Month 12 ) , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Any medically diagnose suspect immunodeficient condition ( HIV HIV seropositive subject ) , base medical history , physical examination and/or laboratory test result . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine/control plan administration study period . Enrolment postpone subject outside specify window . Administration trimethoprim/sulphamethoxazole within 7 day first dose study vaccine/control , plan administration trimethoprim/sulphamethoxazole within 7 day first dose study vaccine/control . Current drug alcohol abuse .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>HPV</keyword>
	<keyword>Human papillomavirus ( HPV ) vaccine</keyword>
	<keyword>Human Immunodeficiency Virus ( HIV )</keyword>
	<keyword>Cervical cancer</keyword>
	<keyword>Papillomavirus</keyword>
</DOC>